R&D has been a serious commitment of Tecnifar over the last 20 years.
We believe in research as a way to contribute to the advancement of medical sciences through the research and development of new medicines.
Focused on the patient’s needs, we focus on developing medicines or pharmaceutical forms for which there is a therapeutic gap or which add value to existing therapies.
Our main area of research has been the area of bacteriophage therapy. We are committed to developing innovative and disruptive biological therapy to combat serious bacterial infections or those that are multi-resistant to conventional antibiotics.
Lead product, TP-122
We are currently developing the lead product, TP-122 – a new biological medicine intended for the treatment of severe respiratory infections that are multi-resistant to conventional antibiotics. Once the pre-clinical phase is complete, TP-122 is expected to enter clinical trials in 2023. We expect to complete clinical development in the next 5 years and place the first biological medicine on the international market in 2028.
Our main focus has been the area of the Central Nervous System, where we pioneered unique molecules in the Portuguese medicinal arsenal, such as semisodium valproate, nortriptyline and cetazolam.
As a result of these developments and collaborations, we have achieved the opening of new geographies in a logic of internationalization of Tecnifar’s own products.
